<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Manag Care Spec Pharm</journal-id><journal-id journal-id-type="iso-abbrev">J Manag Care Spec Pharm</journal-id><journal-id journal-id-type="pmc-domain-id">4474</journal-id><journal-id journal-id-type="pmc-domain">jmcsp</journal-id><journal-id journal-id-type="publisher-id">jmcsp</journal-id><journal-title-group><journal-title>Journal of Managed Care &amp; Specialty Pharmacy</journal-title></journal-title-group><issn pub-type="ppub">2376-0540</issn><issn pub-type="epub">2376-1032</issn><publisher><publisher-name>Academy of Managed Care Pharmacy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10390979</article-id><article-id pub-id-type="pmcid-ver">PMC10390979.1</article-id><article-id pub-id-type="pmcaid">10390979</article-id><article-id pub-id-type="pmcaiid">10390979</article-id><article-id pub-id-type="pmid">32011960</article-id><article-id pub-id-type="doi">10.18553/jmcp.2020.26.2.176</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone
Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with
Schizophrenia</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>El Khoury</surname><given-names initials="AC">Antoine C.</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pilon</surname><given-names initials="D">Dominic</given-names></name><degrees>MA</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morrison</surname><given-names initials="L">Laura</given-names></name><degrees>MSc</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shak</surname><given-names initials="N">Nina</given-names></name><degrees>BA</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Llaneza</surname><given-names initials="A">Amanda</given-names></name><degrees>BA</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="E">Edward</given-names></name><degrees>MD, MBA</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lefebvre</surname><given-names initials="P">Patrick</given-names></name><degrees>MA</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><aff id="aff1"><label>1</label>Janssen Scientific Affairs, Titusville, New Jersey.</aff><aff id="aff2"><label>2</label>Analysis Group, Montr&#233;al, Quebec, Canada.</aff><aff id="aff3"><label>3</label>Analysis Group, Menlo Park, California</aff><aff id="aff4"><label>4</label>HireGenics, Duluth, Georgia.</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>AUTHOR CORRESPONDENCE: Antoine C. El Khoury, PhD, Janssen
Scientific Affairs, 1125 Trenton Harbourton Rd., Titusville, NJ 08560. E-mail:
<email>AKhour@its.jnj.com</email>.</corresp><fn fn-type="COI-statement"><p>This research was funded by Janssen Scientific Affairs. Pilon, Morrison, Lefebvre, and
Shak are employees of Analysis Group, a consulting company that received research grants
from Janssen Scientific Affairs to conduct this study. El Khoury and Kim are employees
of Janssen Scientific Affairs. At the time this study was conducted, Llaneza was an
employee of HireGenics, which provided services to Janssen Scientific Affairs for the
study.</p><p>Part of the material in this manuscript was presented at the Academy of Managed Care
Pharmacy 2019 Annual Meeting; March 25-29, 2019; San Diego, CA.</p></fn></author-notes><pub-date pub-type="ppub"><month>2</month><year>2020</year></pub-date><volume>26</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">442058</issue-id><elocation-id>10.18553/jmcp.2020.26.2.176</elocation-id><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-04 03:25:19.917"><day>04</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2020, Academy of Managed Care Pharmacy. All rights
reserved.</copyright-statement><copyright-year>2020</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jmcp.2020.26.2.176.pdf"/><abstract><sec><title>BACKGROUND:</title><p>Recent evidence has demonstrated that, over 12 months, pharmacy costs associated with
switching nonadherent recently relapsed patients from oral atypical antipsychotics
(OAAs) to once-monthly paliperidone palmitate (PP1M) were offset by reduced relapse
rates and schizophrenia-related health care costs. In addition, earlier use of PP1M may
generate greater cost savings.</p></sec><sec><title>OBJECTIVE:</title><p>To project the long-term economic impact when a proportion of nonadherent patients with
a recent relapse switch from OAAs to PP1M.</p></sec><sec><title>METHODS:</title><p>A 36-month decision-tree model with twelve 3-month cycles was developed from a Medicaid
payer&#8217;s perspective. The target population was nonadherent, recently relapsed OAA
patients. At equal adherence, probability of relapse was equal between PP1M and OAAs,
and OAA patients were nonadherent until treatment switch. Event rates (adherence,
relapse, and switch) and cost inputs (pharmacy and relapse) were based on the
literature, and rates remained constant. Outcomes included number of relapses, pharmacy
costs, and relapse costs (2017 U.S. dollars) at years 1, 2, and 3. One-way sensitivity
(OSA) and probabilistic sensitivity analyses (PSA) evaluated the effect of varying model
inputs on health plan and per-patient level costs.</p></sec><sec><title>RESULTS:</title><p>Based on a hypothetical health plan of 1 million members, 3,037 OAA patients were
recently relapsed and nonadherent. Compared with continuing OAAs, switching 5% of
patients (n = 152) to PP1M resulted in net cost savings of $674,975, $723,298, and
$562,310 at the plan level; $4,445, $4,764, and $3,703 per patient switched per year;
and $0.0562, $0.0603, and $0.0469 per member per month in years 1, 2, and 3,
respectively, resulting in total plan-level savings of &gt; $1.9 million over 3 years. A
total of 221 relapses were avoided (year 1: 92; year 2: 72; and year 3: 57). In years 1,
2, and 3, respectively, total annual plan-level schizophrenia-related costs were $114.1
million, $107.2 million, and $105.8 million when all patients switched to PP1M before
any subsequent relapse (n = 3,037); $123.4 million, $109.6 million, and $106.7 million
when patients switched to PP1M after a first subsequent relapse (n = 2,631); and $127.6
million, $121.6 million, and $117.0 million when all patients remained on OAAs. The cost
per patient switched to PP1M was lower when all patients received PP1M before a
subsequent relapse versus after their first subsequent relapse at all years (year 1:
$37,559 vs. $45,089; year 2: $35,288 vs. $36,321; and year 3: $34,826 vs. $35,155). OSA
demonstrated consistent net cost savings per patient switched, ranging from $640 to
$10,484 (year 1); $1,774 to $9,245 (year 2); and $1,354 to $7,026 (year 3). PSA
demonstrated 96.3%, 99.7%, and 99.7% of iterations were cost saving in years 1, 2 and 3,
respectively.</p></sec><sec><title>CONCLUSIONS:</title><p>Pharmacy costs associated with switching nonadherent OAA patients with a recent relapse
to PP1M were offset by reduced relapse rates and health care costs at years 1, 2, and 3,
with earlier use of PP1M resulting in increased cost savings at all years.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>